National Institutes of Health (NIH)
Components of Participating Organizations
National Institute of Neurological Disorders andStroke (NINDS)
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
- April 4, 2024- Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084.
- August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See NoticeNOT-OD-22-198.
- August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
PAR-25-058,R61/R33Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
PAR-25-060,R61/R33Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
This Notice of Funding Opportunity (NOFO) encourages research grant applications to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders.This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE).
This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
Key Dates
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
February 18, 2025 | February 18, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
June 18, 2025 | June 18, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
October 20, 2025 | October 20, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
February 18, 2026 | February 18, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
June 18, 2026 | June 18, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
October 20, 2026 | October 20, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
February 18, 2027 | February 18, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
June 18, 2027 | June 18, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
October 20, 2027 | October 20, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Required Application Instructions
It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).
Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
IMPORTANT: Per NOT-OD-24-086 updated application forms (FORMS-I) will be used for this opportunity. The updated forms are not yet available and will be posted 30 calendar days or more prior to the first application due date. Once posted, you will be able to access the forms using one of the following submission options:
- NIH ASSIST
- An institutional system-to-system (S2S) solution
- Grants.gov Workspace
Table of Contents
Part 1. Overview Information
Key Dates
Part 2. Full Text of Announcement
Section I. Notice of Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
Section I. Notice of Funding Opportunity Description
This notice of funding opportunity (NOFO) is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to encourage the translation of research discoveries into new treatments for disorders that fall under the NINDS mission.
R61/R33 Mechanism
This NOFO uses the R61/R33 Phased Innovation Award mechanism in which the R61 phase is generally utilized to support preparatory or prerequisite activities that establish feasibility for execution of the R33 phase. The R61 and R33 phases cannot overlap in time.By design, this R61/R33 supports dependent aims; the R33 depends on the R61. The risk of dependent aims is mitigated by milestones between the R61 and R33 (discussed in detail below). Only if the milestones are met does the project progress from the R61 to the R33.
NOFO Scope
R61 activities include (but are not limited to) set up and optimization, standardization, and validation of measures of fundamental cellular/molecular events such as binding, bioactivity at the target, and activity downstream of the target relevant to neurological function. Phenotypic assays are also supported. In vitro (such as single or multiple cell systems), ex vivo and/or non-mammalian in vivo (such as zebrafish or fruit fly) assays may be used. The proposed assays should have sufficient throughput and robustness forthe intended screening activities. Pilot screening as part of assay validation is also supported. This NOFO is not intended for extensive development and validation of disease-relevant models or endpoints for proof-of-concept in vivo efficacy testing; such projects should instead use PAR-25-060 Except for limited studies of target deconvolution following phenotypic screening, projects designed for target identification are not covered under this NOFO.
Inthe R33 phase, both small molecule and biologic (such as peptides, proteins, oligonucleotides, etc.) screening efforts are supported. Therapeutic agent identification often requires multiple tiers of screens for finding active agents, confirming activity, testing selectivity, ruling out artifacts, etc. The R33 also includes preparation of a focused set of small molecule or biologic hits and characterization thereof. This NOFO does not support optimization of potential therapeutic agents. For this NOFO, optimization is defined as the rational, iterative design of new agents based on data obtained in the prior iteration. This is distinct from screening, which for this NOFO is defined as systematically testing a pre-defined library of agents.
Further development of potential therapeutic agents identified in IGNITE-supported screening efforts can be supported in later-stage programs such as the NIH Blueprint Neurotherapeutics Program (BPN) for Small Molecules, NIH BPN-Biologics, NIH SBIR/STTR, or other private or public sources.
Phased Award Milestones
Transition from the R61 to the R33 phase is contingent upon the successful completion of proposed milestones. Milestones are metrics that are quantifiable for measuring success that can be used for go/no-go decision-making at the R61/R33 transition point and should have timelines and quantitative criteria associated with them. NINDS emphasizes the importance of the robustness and reproducibility of experimental results in evaluating progress (see https://www.ninds.nih.gov/funding/preparing-your-application/preparing-research-plan/rigorous-study-design-and-transparent-reporting). Specific Aims or a list of activities planned for each year are not considered milestones because they do not provide decision-making goals. Section IV includes additional information regarding project milestones. For milestone examples, please see https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research/Funding-Programs-Researchers/IGNITE.
Rigor of Experimental Data
NINDS, as part of NIH, strives for rigor and transparency in all research it funds. For this reason, NINDS explicitly emphasizes the NIH application instructions related to rigor and transparencyand provides additional guidance to the scientific community. For example, the biological rationale for the proposed experiments must be based on rigorous and robust supporting data, which means that data should be collected via methods that minimize the risk of bias and be reported in a transparent manner. If previously published or preliminary studies do not meet these standards, applicants should address how the current study design addresses the deficiencies in rigor and transparency. Proposed experiments should likewise be designed in a manner that minimizes the risk of bias and ensures validity of experimental results.
Rigor is particularly important for translational work, which forms a foundation for further development of potential therapeutic agents. Rigorous assay development involves validating that the assays are robust and have appropriate throughput for the intended screen. This includes signal-to-noise assessments (such as Z' scores) as well as day-to-day, plate-to-plate or batch-to-batch reproducibility validations. More information on assay validation can be found in the NCATS assay guidance manual.
Entry Criteria:
- Novelty: Applications appropriate for this NOFO are those with plans for development of assays and screens for novel targets that are a significant improvement over existing approaches and have the potential to lead to novel therapeutics for neurological disorders.
- Biological rationale and preliminary data: Projects appropriate for this NOFO must have a strong biological rationale for the intended approach. Preliminary data should reflect rigorous, well-designed experiments (either from the literature, data from other sources, or, when available, from investigator-generated data). Examples of the most critical elements for a well-designed study are summarized on the NINDS website (https://www.ninds.nih.gov/Funding/grant_policy).
- Relevance for therapy development: Projects appropriate for this NOFO should aim to develop novel therapeutic agents that can be advanced towards development for neurological or neuromuscular disorders. Applications should illustrate how the assays will be used to identify candidate therapeutics and should include a plan for identification of preliminary therapeutic agents.
The R61 phase is for the development and validation of assays to support a distinct testing funnel, including but not limited to:
- Assays to evaluate potency, specificity, selectivity, purity, identity, or stability of therapeutic agents
- Binding or other assays
- Assays to rule out screening artifacts
- Assays for biophysical characterization of secondary or tertiary structure, conformational stability, aggregation, or oligomerization
- Assays to evaluate cellular uptake, target engagement, transduction/infection, and downstream functional read-outs
- Preparation of reagents and tool agents to enable optimization of assays
- Optimization of assays for medium- or high-throughput screening (HTS)
- For use and development of iPSC lines, please see NOT-NS-24-019
Examples of activities for the R33 phase include, but are not limited to:
- HTS, comprising screening of libraries for activity against biological targets via the use of automation, miniaturized assays and large-scale data analysis
- Preparation and screening of focused or select libraries of potential therapeutic agents
- Preparation of 'hit' therapeutic agents and confirmation of structure, sequence or biological characteristics
- Assessment of therapeutic agents properties using computational analysis and early physicochemical measurements, such as polar surface area, solubility, cell permeability and efflux
- Assessment of initial in vitro parameters such as absorption, distribution, metabolism, and excretion (ADME)
- Assessment of potential off-target activities
Collaborations
Developing therapeutics requires a multidisciplinary approach. Investigators are encouraged to form collaborations with those familiar with successful drug/biologic development as well as those familiar with what the desired end product should look like (such as clinicians and biostatisticians). Applicants should consider how they will identify and foster relationships with potential licensing and commercialization partners early in the therapy development process once an award is made. PDs/PIs are expected to work closely with their institutional technology transfer officials to ensure that royalty agreements, patent filings, and all other necessary IP arrangements are completed in a timely manner and that commercialization plans are developed and updated over the course of the project.
Additional Considerations:
- Applicants are strongly encouraged to contact NINDS Scientific/Research Staff to discuss potential research projects prior to submitting an application. This is to ensure this is the right NOFO and institute for your project and to help make sure critical elements (such as milestones and phases) are included.
2. Small Business applicants who are eligible for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are strongly encouraged to submit through either the SBIR or STTR Omnibus Solicitations or other appropriate SBIR or STTR funding opportunities to take advantage of the congressionally mandated set-aside specifically for small businesses. Please see https://www.ninds.nih.gov/Funding/Small-Business-Grantsfor more information about the programs.
3. Prior to funding an application, NINDS Program staff may contact the applicant to discuss the proposed milestones and any changes suggested by the NINDS review panel or Program staff. A final set of approved milestones will be specified in the Notice of Award.
Leveraging Existing Resources
Additional information on guidance for assay development may be found in the online comprehensive Assay Guidance Manual (http://www.ncbi.nlm.nih.gov/books/NBK53196/), HTS assay protocols deposited in the PubChem BioAssay Database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=pcassay) as well as the published literature. One notable publicly available natural products library is managed by the National Cancer Institute (https://dtp.cancer.gov/organization/npb/introduction.htm).
Applications Not Responsive to this NOFO:
Non-responsive studiesinclude those that involve any of the following activities:
- Applications containing the following later-stage activities:
- Medicinal chemistry optimization or Structure-Activity-Relationship (SAR) studies for small molecules (for support for this work, please consider PAR-24-043)
- Optimization for biologics (for support for this work, please consider PAR-24-293
- Investigational New Drug (IND) enabling studies
- Manufacture of therapeutic agents for clinical use
- Development of bioassays for clinical use
- Applications containing the following basic science activities:
- Studies designed to establish proof of concept for a biological target or use of agents to identify targets relevant to a disease, except for limited studies to deconvolute the target of phenotypic screen hits
- Studies of disease mechanism
- Development of assays or probes to support basic understanding of disease or other basic research
- Applications containing the following activities covered in companion IGNITE NOFOs:
- In vivo proof of concept efficacy studies in a mammalian disease model (for support for this work, please considerPAR-25-058
- Applications with a significant focus (e.g. an entire aim) on developing pharmacodynamic biomarkers
- Discovery and development of diagnostic, monitoring, predictive or prognostic biomarkers (for support for this wok, please consider the NINDS Biomarker Program)
- Development of devices (for support for this work, please consider the NINDS Translational Devices Program) device/drug combinations, surgical procedures, diagnostics, and rehabilitation strategies
- Projects that are entirely in silico
Applications that are missing any of the following will be deemed to be incomplete and will be withdrawn and not reviewed:
- Activities for both the R61 and R33 phases with a clear demarcation of which activities are in the R61 phase and which are in the R33 phase, as described in Section IV.2. The R61 and R33 phases cannot overlap in time; they are separate, sequential phases.
- Quantitative go/no-go milestones as an attachment, as described in Section IV.2.
- PEDP attachment, as described in Section IV.2
See Section VIII. Other Information for award authorities and regulations.
Plan for Enhancing Diverse Perspectives (PEDP)
The NIH recognizes that teams comprised of investigators with diverse perspectives working together and capitalizing on innovative ideas and distinct viewpoints outperform homogeneous teams. There are many benefits that flow from a scientific workforce rich with diverse perspectives, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust.
To support the best science, the NIH encourages inclusivity in research guided by the consideration of diverse perspectives. Broadly, diverse perspectives can include but are not limited to the educational background and scientific expertise of the people who perform the research; the populations who participate as human subjects in research studies; and the places where research is done.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Assessment of applications containing a PEDP are based on the scientific and technical merit of the proposed project. Consistent with federal law, the race, ethnicity, or sex (including gender identify, sexual orientation, or transgender status) of a researcher, award participant, or trainee will not be considered during the application review process or when making funding decisions.Applications that fail to include a PEDP will be considered incomplete and will be administratively withdrawn before review.
The PEDP will be submitted as Other Project Information as an attachment (see Section IV). Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP Guidance materials.
Section II. Award Information
Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
TheOER Glossaryand the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Need help determining whether you are doing a clinical trial?
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Direct costs cannot exceed $499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed $750,000.
The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. (For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.)
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Section III. Eligibility Information
1. Eligible Applicants
Higher Education Institutions
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
For-Profit Organizations
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)
Local Governments
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized).
Federal Government
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession
Other
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Organizations).
Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the How to Apply-Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference theNIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.
- System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
- NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
- eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing theirGrants.gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019 and Notice of NIH's Interest in Diversity, NOT-OD-20-031.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply- Application Guide.
2. Cost Sharing
This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1.2 Definition of Terms.
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application.This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Section IV. Application and Submission Information
1. Requesting an Application Package
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the Research (R) Instructions in theHow to Apply - Application Guideexcept where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Page Limitations
All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed.
Instructions for Application Submission
The following section supplements the instructions found in the How to Apply- Application Guide and should be used for preparing an application to this NOFO.
SF424(R&R) Cover
All instructions in the How to Apply- Application Guide must be followed.
SF424(R&R) Project/Performance Site Locations
All instructions in the How to Apply-Application Guide must be followed.
SF424(R&R) Other Project Information
All instructions in the How to Apply-Application Guide must be followed.
Other Attachment #1: Milestones (required, 1-page limit)
Transition from the R61 to the R33 phase is contingent upon the successful completion of one set of proposed milestones. These milestones will be evaluated as part of the scientific and technical merit of the R61/R33 application. The milestones proposed in the application must be well-described, quantifiable, and scientifically justified to allow program staff to assess progress in the R61 phase. In addition, milestones should reflect the objectives of the applicationand be appropriate for the therapeutic approach, stage of development, and indication. Rationale should be provided for the choice of measures and values proposed for the milestones. Specific aims or a list of activities are not considered milestones because they would not provide decision-making goals. A discussion of the milestones relative to the progress of the R61 phase and the implications of successful completion of the milestones for the R33 phase should be included. The clarity and completeness of the R61/R33 application with regard to specific goals and feasibility milestones are critical. Milestones should provide clear indicators of a project's continued success or emergent difficulties and will be used to evaluate the application as part of the consideration of the awarded project for further funding of non-competing award years by the Program Director(s)/Principal Investigator(s), and Program Official(s). For example, to reflect that an assay is fully validated and able to support R33 activities, one milestone could be to demonstrate assay robustness (e.g. Z' score of specified level), reproducability (e.g. r2 of a specified level) and throughput. Applicants should propose milestones based on their particular project and should measure success of all essential R61 activities. More example milestones can be found at https://www.ninds.nih.gov/Funding/Apply-Funding/Application-Support-Library/IGNITE-Milestone-Examples. The existence of clear, quantitative, go/no-go milestones for transition from the R61 to the R33 phase isa requirement for this NOFO. Applications lacking an attached milestone document will be administratively withdrawn without review.
Other Attachment #2:Intellectual Property (required, 1-page limit)
Applications must include an Intellectual property (IP) strategy. Applicants are encouraged to prepare this section of the application in consultation with their institution's technology transfer officials.
Applicants should describe the IP landscape surrounding their therapy and assay. Applicants should describe any known constraints that could impede their therapeutic discovery and development (e.g., certain restrictions under transfer or sharing agreements, applicants' previous or present IP filings and publications, applicant's out-licensing agreements, similar therapies that are under patent protection and/or on the market, etc.) and how these issues could be addressed with achieving the goals of this program. If the applicant proposes using an agent(s) whose IP is not owned by the applicant's institution, either an investigational therapeutic, FDA-approved therapeutic, or other licensed product, the applicant should include a letter (see letter of support) from any entities owning the IP indicating there will not be any limitations imposed on the studies or the product which would impede achieving the goals of the funding program.
If patents pertinent to the therapy being developed under this application have been filed, the applicant should indicate the details of filing dates, what type of patents are filed, and application status, and associated USPTO links, if applicable.
Applicants should also discuss future IP filing plans. For a multiple-PD/PI, multiple-institution application, applicants should describe the infrastructure of each institution for bringing the technologies to practical application and for coordinating these efforts (e.g., licensing, managing IP) among the institutions. Applicants should clarify how IP will be shared or otherwise managed if multiple PD/PIs and institutions are involved, consistent with achieving the goals of the program.
For information on exceptions to the NIH data sharing policy due to intellectual property considerations, please see here: https://sharing.nih.gov/faqs#/data-management-and-sharing-policy.htm?anchor=56972. Applicants are encouraged to contact the NINDS Scientific/Research Staffif they have any questions or concerns
Plan for Enhancing Diverse Perspectives (PEDP)
- In an "Other Attachment" entitled "Plan for Enhancing Diverse Perspectives," all applicants must include a summary of strategies to advance the scientific and technical merit of the proposed project through expanded inclusivity.
- Applicants should align their proposed strategies for PEDP with the research strategy section, providing a holistic and integrated view of how enhancing diverse perspectives and inclusivity are buoyed throughout the application.
- The PEDP will vary depending on the scientific aims, expertise required, the environment and performance site(s), as well as how the project aims are structured.
- The PEDP may be no more than 2 pages in length and should include:
- Actionable strategies using defined approaches for the inclusion of diverse perspectives in the project;
- Description of how the PEDP will advance the scientific and technical merit of the proposed project;
- Anticipated timeline of proposed PEDP activities;
- Evaluation methods for assessing the progress and success of PEDP activities.
Examples of items that advance inclusivity in research and may be appropriate for a PEDP can include, but are not limited to:
- Partnerships with different types of institutions and organizations (e.g., research-intensive; undergraduate-focused; HBCUs; emerging research institutions; community-based organizations).
- Project frameworks that enable communities and researchers to work collaboratively as equal partners in all phases of the research process.
- Outreach and planned engagement activities to enhance recruitment of individuals from diverse groups as human subjects in clinical trials, including those from underrepresented backgrounds.
- Description of planned partnerships that may enhance geographic and regional diversity.
- Outreach and recruiting activities intended to diversify the pool of applicants for research training programs, such as outreach to prospective applicants from groups underrepresented in the biomedical sciences, for example, individuals from underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women.
- Plans to utilize the project infrastructure (i.e., research and structure) to enhance the research environment andsupport career-advancing opportunities for junior, early- and mid-career researchers.
- Transdisciplinary research projects and collaborations among researchers from fields beyond the biological sciences, such as physics, engineering, mathematics, computational biology, computer and data sciences, as well as bioethics.
Examples of items that are not appropriate in a PEDP include, but are not limited to:
- Selection or hiring of personnel for a research team based on their race, ethnicity, or sex (including gender identity, sexual orientation, or transgender status).
- A training or mentorship program limited to certain researchers based on their race, ethnicity, or sex (including gender identity, sexual orientation, or transgender status).
For further information on the Plan for Enhancing Diverse Perspectives (PEDP), please see PEDP Guidance materials.
SF424(R&R) Senior/Key Person Profile
All instructions in the How to Apply- Application Guide must be followed.
R&R Budget
All instructions in the How to Apply- Application Guide must be followed.
PEDP implementation costs:
Applicants may include allowable costs associated with PEDP implementation (as outlined in the Grants Policy Statement section 7): https://grants.nih.gov/grants/policy/nihgps/html5/section_7/7.1_general.htm.
R&R Subaward Budget
All instructions in the How to Apply-Application Guide must be followed.
PHS 398 Cover Page Supplement
All instructions in the How to Apply- Application Guide must be followed.
PHS 398 Research Plan
All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:
Specific Aims: Within the Specific Aims section, include headers titled R61 Phase Specific Aims and R33 Phase Specific Aims. Under each header, state the specific objectives of the efforts, including the technical questions you will try to answer to determine the feasibility of the proposed approach. Since the goal of the R61 phase of this NOFO is the development and validation of assays, hypothesis testing, per se, may not be the driving force in developing such an application, and therefore, may not be applicable in the R61 phase.
Research Strategy: Applications funded through this opportunity should provide a strong biological rationale, which includes evidence to support the novelty and/or unmet medical need for the therapeutic target or therapeutic approach. In addition, the rationale should provide evidence supporting the unmet need for the assays and a discussion of the role the assays will play in the therapeutic discovery decision-making process for the intended therapeutic target (therapeutic discovery plan). Supporting information, which addresses the biological rationale and the unmet need for the assays to be developed, is required. NINDS urges investigators to follow the NIH guidance for rigor and transparency in grant applicationsand additionally recommends the research practices described atRigorous Study Design and Transparent Reporting.This will ensure that robust experiments are designed, potential experimenter biases are minimized, results and analyses are transparently reported, and results are interpreted carefully. These recommended research practices include, where applicable, expressing clear rationale for the chosen model(s) and primary/secondary endpoint(s), describing tools and parameters clearly, blinding, randomizing, ensuring adequate sample size, pre-specifying inclusion/exclusion criteria, appropriately handling missing data and outliers, implementing appropriate controls, preplanning analyses, and using appropriate quantitative techniques. It is also strongly recommended to indicate clearly the exploratory vs. confirmatory components of the study, consider study limitations, and plan for transparent reporting of all methods, analyses, and results so that other investigators can evaluate the quality of the work and potentially perform replications.
Investigators should indicate whether data presented or cited in the application as key support for the proposed work were collected, analyzed, and reported in a rigorous and transparent manner as indicated above. A plan to address any ambiguity, weaknesses, or limitations in the prior research should be included in the application. Proposed experiments should similarly adhere to these high standards of rigor and transparency.
Applications should also address the methods and rationale for an assay validation plan in a thorough and carefully thought-out manner. Assay validation is a process that determines the fitness of an assay, which has been properly developed, optimized and standardized, for an intended purpose. Assay validation should be clearly outlined to cover critical topics such as but not limited to i) definition of the intended purpose(s), ii) optimization, iii) standardization, iv) reproducibility, v) sensitivity, vi) specificity, vii) thresholds (cut-offs), and viii) throughput. In order to assess the predictive value of preclinical research, sufficient information should be available about study design, execution, analysis, and interpretation. Discussions should include how decisions will be made about small molecule or biologic agent prioritization based on screening results and druggability characteristics. Applicants should discuss the plans to characterize the hits. This could include in vitro ADME properties, pharmacokinetics or distribution, or biophysical characteristics or target deconvolution if using a phenotypic assay.
Within the Research Strategy, applicants must describe both the R61 phase and the R33 phase, including the R61/R33 transition point, and timeline. Applicants should clearly outline the rationale for choosing the proposed studies, the choice of library, target or pathway, and how it fits within the therapeutic discovery plan. The research strategy for the R61 phase should address the validation status of proposed assays. The application should describe how the assays developed in the R61 phase will be implemented in the R33 phase, and how decisions about which compounds/biological agents to advance will be made. As this is an R61/R33 mechanism, both phases must be requested and planned, and the two phases must not overlap in time. Applications that do not clearly demarcate the R61 and R33 phases will be administratively withdrawn.
Novelty of the therapeutic strategy/target over whats currently available in the clinic or under therapeutic development should be emphasized. A description of the therapeutic strategy in relation to the state of the field should be included.
Timeline:Provide a timeline with specific milestones for progression from the R61 phase to the R33 phase. The timeline, specific goals and feasibility milestones should be clear and complete. Indicate when it is anticipated that essential components of the project (e.g., set up and validation of assay) will be completed. The proposed timeline with specific milestones should be clearly delineated and should appear as the last element of the Research Strategy section.
Therapeutic Discovery Plan: It is essential for applicants to include, within the Research Strategy, a description of how knowledge gained from this work will support future therapeutic discovery efforts beyond the project period through to early clinical trials. As part of this consideration, attention should be paid to the intended patient population such that appropriate experiments (assays, targets, modalities, etc.) are used in the current application.
Collaboration: NINDS strongly encourages applicants to form multidisciplinary teams that consist of academic/industry experts relevant to the research plan (i.e., biostatisticians, clinicians, drug development experts, technical experts). This multidisciplinary team should be able to define the goals of the research, outline specific gaps that need to be addressed during this funding period, outline detailed plans and experiments, andexecute the research strategy. The team should also have the expertise to anticipate and mitigate potential future therapy develop hurdles that could be encountered as part of the larger therapy development plan
Resource Sharing Plan:Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply- Application Guide.
Other Plan(s):
All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:
- All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.
Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply- Application Guide.
- No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.
PHS Human Subjects and Clinical Trials Information
When involving human subjects research, clinical research, and/or NIH-definedclinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the How to Apply- Application Guide must be followed.
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the How to Apply-Application Guide must be followed.
PHS Assignment Request Form
All instructions in the How to Apply-Application Guide must be followed.
Foreign Organizations
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the How to Apply-Application Guide.
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.
4. Submission Dates and Times
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIHs electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the How to Apply- Application Guide.
5. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
6. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in theNIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.
7. Other Submission Requirements and Information
Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.
The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organizations profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.
See more tips for avoiding common errors.
Applications must include a PEDP submitted as Other Project Information as an attachment. Applications that fail to include a PEDP will be considered incomplete and will be administratively withdrawn before review.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.
Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures,2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.35.
Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to theHHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov.
Post Submission Materials
Applicants are required to follow the instructions for post-submission materials, as described in the policy
Section V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following scored review criteria and additional review criteria (as applicable for the project proposed). An application does not need to be strong in all categories to be judged likely to have a major scientific impact. As part of the overall impact score, reviewers should consider and indicate how the plan to enhance diverse perspectives affects the scientific merit of the project.
Review Criteria
Reviewers will consider Factors 1, 2 and 3 in the determination of scientific merit, and in providing an overall impact score. In addition, Factors 1 and 2 will each receive a separate factor score.
Factor 1: Importance of the Research
Significance
- Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly. Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.
- Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g. prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.
Innovation
- Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.
- Evaluate whether the proposed work applies novel concepts, methods or technologies, or uses existing concepts, methods, technologies in novel ways, to enhance the overall impact of the project.
Specific to this NOFO:
- Evaluate whether a successful therapeutic would be a significant improvement over existing therapy and is based on an understanding of the therapeutic landscape for the desired indication
- Evaluate whether the applicants have an understanding of which patient population would likely benefit from a successful therapeutic
- Evaluate whether the starting early-stage agents and libraries are well-chosen given the known challenges therapy development
- Evaluate the novelty of the target, modality, and/or approach to therapy development
Factor 2. Rigor and Feasibility
Approach
- Evaluate the scientific quality of the proposed work. Evaluate the likelihood that compelling, reproducible findings will result (rigor) and assess whether the proposed studies can be done well and within the timeframes proposed (feasibility).
Rigor:
- Evaluate the potential to produce unbiased, reproducible, robust data.
- Evaluate the rigor of experimental design and whether appropriate controls are in place.
- Evaluate whether the sample size is sufficient and well-justified.
- Assess the quality of the plans for analysis, interpretation, and reporting of results.
- Evaluate whether the investigators presented adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.
- For applications involving human subjects or vertebrate animals, also evaluate:
- the rigor of the intervention or study manipulation (if applicable to the study design).
- whether outcome variables are justified.
- whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.
- whether the sample is appropriate and sufficiently diverse to address the proposed question(s).
- For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.
Feasibility:
- Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.
- For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex/gender categories.
- For clinical trial applications, evaluate whether the study timeline and milestones are feasible.
Specific to this NOFO:
- Evaluate whether the proposed approach will result in assays that are robust, reproducible, have appropriate throughput and will measure the appropriate outcomes
- Evaluate whether the screening funnel is appropriate and if plans for prioritizing hits clear and likely to result in selection of agents appropriate for the next stages of research
- Evaluate plans for characterizing hits, if included
- Milestones and timeline:
- Evaluate the robustness and clarity of the milestones; they should be quantitative enough to allow for go/no-go decisions
- Evaluate whether the milestones reflect success of the R61 and that the R33 is feasible and worthwhile
- Evaluate the feasibility of completing the assay development before the R61/R33 transition point
- Evaluate whether the overall timeline is realistic and includes the necessary steps but is also efficient without unnecessary steps
Factor 3. Expertise and Resources
Investigator(s)
- Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work. For Multiple Principal Investigator (MPI) applications, assess the quality of the leadership plan to facilitate coordination and collaboration.
Environment
- Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.
Specific to this NOFO:
- Evaluate whether the investigator team is knowledgeable and experienced with the proposed biological target as well as the therapy development process. Evaluate whether the team has the expertise to not only do the proposed experiments but also to anticipate and mitigate issues that might arise in future therapy development. Evaluate whether adequate effort is being dedicated to the project.
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to theGuidelines for the Review of Human Subjects.
Vertebrate Animals
When the proposed research includes Vertebrate Animals, evaluate the involvement of live vertebrate animals according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. For additional information on review of the Vertebrate Animals section, please refer to theWorksheet for Review of the Vertebrate Animals Section.
Biohazards
When the proposed research includes Biohazards, evaluate whether specific materials or procedures that will be used are significantly hazardous to research personnel and/or the environment, and whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not Applicable
Revisions
Not applicable
Additional Review Considerations
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Specific for this NOFO:
- Intellectual Property (IP) Strategy
- Evaluate whether the application outlines any known constraints that could impede the therapeutic from being developed (e.g., certain restrictions under transfer or sharing agreements, applicants' previous or present IP filings and publications, applicant's out-licensing agreements, similar therapies that are under patent protection and/or on the market, etc) and how these issues could be addressed while achieving the goals of the program
- If applicable, evaluate how strong the applicant's IP portfolio/position (pertinent to the proposed project) is, and to what extent the applicant has a reasonable strategy to protect its IP going forward. If the applicant has filed patents pertinent to the assay, do they provide details about those patents? If IP will be shared among co-investigators, evaluate whether the applicant provide details about the plans for IP sharing
Authentication of Key Biological and/or Chemical Resources:
For projects involving key biological and/or chemical resources, evaluate the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Evaluate whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
PEDP implementation costs: Applicants may include allowable costs associated with PEDP implementation (as outlined in the Grants Policy Statement section 7): https://grants.nih.gov/grants/policy/nihgps/html5/section_7/7.1_general.htm.
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NINDS, in accordance withNIH peer review policy and procedures, using the statedreview criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions, consistent with applicable law.
- Scientific and technical merit of the proposed project, including the PEDP, as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.
Please note that reviewers will not consider race, ethnicity, age, or gender of a researcher, award participant, or trainee, even in part, in providing critiques, scores, or funding recommendations. NIH will not consider such factors in making its funding decisions.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in theNIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.
Prior to making an award, NIH reviews an applicants federal award history in SAM.gov to ensure sound business practices.An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov. NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicants integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via theeRA Commons.Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in theNIH Grants Policy Statement Section 2.4.4 Disposition of Applications.
Section VI. Award Administration Information
1. Award Notices
A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipients business official.
In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Recipients must comply with any funding restrictions described inSection IV.6. Funding Restrictions. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. For more information on the Notice of Award, please refer to theNIH Grants Policy Statement Section 5. The Notice of Award and NIH Grants & Funding website, see Award Process.
Extending the final budget period for the R61 phase requires the prior approval of the NINDS.
Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
2. Administrative and National Policy Requirements
The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:
- The rules listed at 2 CFR Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.
- All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities.
- If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (HHS-690). To learn more, see the Laws and Regulations Enforced by theHHS Office for Civil Rights website.
- HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigators scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.
All federal statutes and regulations relevant to federal financial assistance, including those highlighted inNIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.
Recipients are responsible for ensuring that their activities comply with all applicable federal regulations. NIH may terminate awards under certain circumstances. See2 CFR Part 200.340 Termination andNIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
3. Data Management and Sharing
Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
4. Reporting
When multiple years are involved, recipients will be required to submit theResearch Performance Progress Report (RPPR)annually and financial statements as required in the NIH Grants Policy Statement Section 8.4.1 Reporting.To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see Post-Award Monitoring and Reporting.
- Recipients will provide updates at least annually on implementation of the PEDP.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement Section 8.6 Closeout. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.
Section VII. Agency Contacts
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
Application Submission Contacts
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threatensubmission by the due date, and post-submission issues)
Finding Help Online:https://www.era.nih.gov/need-help(preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email:GrantsInfo@nih.gov(preferred method of contact)
Telephone: 301-480-7075
Grants.gov Customer Support(Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email:support@grants.gov
Scientific/Research Contact(s)
Becky Roof, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Email: rebecca.roof@.nih.gov
Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke (NINDS)
Email:nindsreview.nih.gov@mail.nih.gov
Financial/Grants Management Contact(s)
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email:ChiefGrantsManagementOfficer@ninds.nih.gov
Section VIII. Other Information
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.